Nasdaq · Healthcare

TREACE MEDICAL CONCEPTS, INC. (TMCI)

As-reported financials and recent SEC filings for TREACE MEDICAL CONCEPTS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$212.7M

Net income

$-59.0M

Net margin

-27.7%

Diluted EPS

$-0.93

ROE

-67.6%

P/E (TTM)

—

Market cap

—

Debt / equity

0.6×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$212.7M	$209.4M	$187.1M	$141.8M	$94.4M
Gross profit	$169.8M	$168.3M	$151.9M	$116.3M	$77.5M
Operating income	$-54.2M	$-55.7M	$-51.4M	$-34.8M	$-16.5M
Net income	$-59.0M	$-55.7M	$-49.5M	$-42.8M	$-20.6M
Diluted EPS	$-0.93	$-0.90	$-0.81	$-0.77	$-0.43

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

4/A2026-06-12

42026-06-11

42026-06-01

42026-05-28

8-K2026-05-20

42026-05-19

42026-05-19

42026-05-19

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on TMCI

Search TREACE MEDICAL CONCEPTS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.